Возможности коррекции нефрогенной анемии у пациента с ВИЧ и хронической болезнью почек

1. Evans M, Bower H, Cockburn E, et al. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. Clin Kidney J. 2020;13(5):821-7. DOI:0.1093/ckj/sfaa054
2. GBD Chronic Kidney Disease Collaboration: Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709-33. DOI:10.1016/S0140-6736(20)30045-3
3. Lim C, Ng RWC, Cheng N, et al. Advance care planning for haemodialysis patients. Cochrane Database Syst Rev. 2016;7(7):CD010737. DOI:10.1002/14651858.CD010737.pub2
4. Locatelli F, Nissenson AR, Barrett BJ, et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease Improving Global Outcomes (KDIGO). Kidney Int. 2008;74:1237-40.
5. Милованова Л.Ю., Милованов Ю.С., Козловская Л.В. Эритропоэтины длительного действия в лечении нефрогенной анемии. Урология и нефрология. Спецвыпуск «Актуальные вопросы нефрологии». 2012;11:16-9 [Milovanova LIu, Milovanov IuS, Kozlovskaia LV. Eritropoetiny dlitel'nogo deistviia v lechenii nefrogennoi anemii. Urologiia i nefrologiia. Spetsvypusk “Aktual'nye voprosy nefrologii”. 2012;11:16-9 (in Russain)].
6. Анемия при хронической болезни почек. Клинические рекомендации. 2024. Режим доступа: https://cr.minzdrav.gov.ru/schema/623_42. Ссылка активна на 18.09.2024 [Anemiia pri khronicheskoi bolezni pochek. Klinicheskie rekomendatsii. 2024. Available at: https://cr.minzdrav.gov.ru/schema/623_42. Accessed: 18.09.2024 (in Russain)].
7. Azmandian J, Abbasi MR, Pourfarziani V, et al. Comparing therapeutic efficacy and safety of epoetin beta and epoetin alfa in the treatment of anemia in end-stage renal disease hemodialysis patients. Am J Nephrol. 2018;48(4):251-9. DOI:10.1159/000493097
8. Oka S, Obata Y, Torigoe K, et al. A comparative study of the hemoglobin-maintaining effects between epoetin beta-pegol and Darbepoetin-alpha in patient with chronic kidney disease during 3 months before dialysis initiation. Drugs R D. 2017;17(3):389-96. DOI:10.1007/s40268-017-0188-6
9. Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs. 2013;73(2):117-30. DOI:10.1007/s40265-012-0002-2
10. Ostrvica E, Mesic E, Ostrvica D, et al. Effectiveness of treating renal anemia in the chronic hemodialyzed patients by Epoetin alpha and beta. Med Arh. 2010;64(1):1-6.
11. Jelkmann W. Renal erythropoietin: properties and production. Rev Physiol Biochem Pharmacol. 1986;104:139-217.
12. Deicher R, Horl WH. Differentiating factors between erythropoiesis stimulating agents: a guide to selection for anemia of chronic kidney disease. Drugs. 2004;64(5):499-509.
13. Sinha SD, Bandi VK, Bheemareddy BR, et al. Efficacy, tolerability, and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase III trial. BMC Nephrol. 2019;20(19):1-9.
14. Carrera F, Burnier M. Use of darbepoetin alfa in the treatment of anemia of chronic kidney disease: clinical and pharmacoeconomic considerations. NDT Plus. 2009;2(1):9-17.
15. Macdougall IC, Kai-Uwe E. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet. 2006;368:947-53. DOI:10.1016/S0140-6736(06)69120-4
16. Abracchio MP, Zanella A. Therapy perspectives. L’eritropoietina e la regolazione della massa eritroide. Adis a Wolter Kluwer business, 2006.
17. Locatelli F, Pozzoni P, Vecchio LD. Recombinant human epoetin beta in the treatment of renal anemia. Ther Clin Risk Manag. 2007;3(3):433-9.
18. Locatelli F, Covic A, Eckardt KU, et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2009;24(2):348-54. DOI:10.1093/ndt/gfn653
19. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial. Ann Intern Med. 1989;111(12):992-1000. DOI:10.7326/0003-4819-111-12-992
20. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 Suppl. 3):S11-145.
21. Locatelli F, Aljama P, Bárány P, et al.; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19 Suppl. 2:ii1-47. DOI:10.1093/ndt/gfh1032
22. Panichi V, Rosati A, Bigazzi R, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant. 2011;26(8):2641-8. DOI:10.1093/ndt/gfq802
23. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17(4):1181-91.
24. de Lurdes Agostinho Cabrita A, Pinho A, Malho A, et al. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. Int Urol Nephrol. 2011;43(3):835-40. DOI:10.1007/s11255-010-9805-9
25. Won HS, Kim HG, Yun YS, et al. IL-6 is an independent risk factor for resistance to erythropoiesis-stimulating agents in hemodialysis patients without iron deficiency. Hemodial Int. 2012;16(1):31-7. DOI:10.1111/j.1542-4758.2011.00635.x
26. Shankar A, Sun L, Klein BE, et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 2011;80(11):1231-8.
27. Stinghen AE, Bucharles S, Riella MC, Pecoits-Filho R. Immune mechanisms involved in cardiovascular complications of chronic kidney disease. Blood Purif. 2010;29(2):114-20. DOI:10.1159/000245636
28. Yilmaz MI, Solak Y, Covic A, et al. Renal anemia of inflammation: the name is self-explanatory. Blood Purif. 2011;32(3):220-5. DOI:10.1159/000328037
29. Bruggeman LA, Bark C, Kalayjian RC. HIV and the Kidney. Curr Infect Dis Rep. 2009;11:479-85.
30. Margolick JB, Jacobson LP, Schwartz GJ, et al. Factors affecting glomerular filtration rate, as measured by iohexol disappearance, in men with or at risk for HIV infection. PLoS One. 2014;9:e86311.
31. Ng DK, Jacobson LP, Brown TT, et al. HIV therapy, metabolic and cardiovascular health are associated with glomerular hyperfiltration among men with and without HIV infection. AIDS. 2014;28:377-86.
32. Lazarus Jeffrey V, Laut KG, Safreed-Harmon K, et al. Disparities in HIV clinic care across Europe: Findings from the EuroSIDA clinic survey. BMC Infect Dis. 2016;16:335. DOI:10.1186/s12879-016-1685-x
33. Mohan S, Herlitz LC, Tan J, et al. The changing pattern of glomerular disease in HIV and hepatitis C co-infected patients in the era of HAART. Clin Nephrol. 2013;79:285-91.
34. Markowitz GS, Nasr SH, Stokes MB, D’Agati VD. Treatment with IFN-alpha, -beta, or -gamma is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5:607-15.
35. Volberding PA, Levine AM, Dieterich D, et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004;38:1454-63.
36. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-23.
37. Kimel M, Leidy NK, Mannix S, Dixon J. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value in Health. 2008;11(1):57-75.
38. Henry DH, Beall GN, Benson CA, et al. Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy. Ann Intern Med. 1992;117(9):739-48. DOI:10.7326/0003-4819-117-9-739

________________________________________________

1. Evans M, Bower H, Cockburn E, et al. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. Clin Kidney J. 2020;13(5):821-7. DOI:0.1093/ckj/sfaa054
2. GBD Chronic Kidney Disease Collaboration: Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709-33. DOI:10.1016/S0140-6736(20)30045-3
3. Lim C, Ng RWC, Cheng N, et al. Advance care planning for haemodialysis patients. Cochrane Database Syst Rev. 2016;7(7):CD010737. DOI:10.1002/14651858.CD010737.pub2
4. Locatelli F, Nissenson AR, Barrett BJ, et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease Improving Global Outcomes (KDIGO). Kidney Int. 2008;74:1237-40.
5. Milovanova LIu, Milovanov IuS, Kozlovskaia LV. Eritropoetiny dlitel'nogo deistviia v lechenii nefrogennoi anemii. Urologiia i nefrologiia. Spetsvypusk “Aktual'nye voprosy nefrologii”. 2012;11:16-9 (in Russain).
6. Anemiia pri khronicheskoi bolezni pochek. Klinicheskie rekomendatsii. 2024. Available at: https://cr.minzdrav.gov.ru/schema/623_42. Accessed: 18.09.2024 (in Russain).
7. Azmandian J, Abbasi MR, Pourfarziani V, et al. Comparing therapeutic efficacy and safety of epoetin beta and epoetin alfa in the treatment of anemia in end-stage renal disease hemodialysis patients. Am J Nephrol. 2018;48(4):251-9. DOI:10.1159/000493097
8. Oka S, Obata Y, Torigoe K, et al. A comparative study of the hemoglobin-maintaining effects between epoetin beta-pegol and Darbepoetin-alpha in patient with chronic kidney disease during 3 months before dialysis initiation. Drugs R D. 2017;17(3):389-96. DOI:10.1007/s40268-017-0188-6
9. Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs. 2013;73(2):117-30. DOI:10.1007/s40265-012-0002-2
10. Ostrvica E, Mesic E, Ostrvica D, et al. Effectiveness of treating renal anemia in the chronic hemodialyzed patients by Epoetin alpha and beta. Med Arh. 2010;64(1):1-6.
11. Jelkmann W. Renal erythropoietin: properties and production. Rev Physiol Biochem Pharmacol. 1986;104:139-217.
12. Deicher R, Horl WH. Differentiating factors between erythropoiesis stimulating agents: a guide to selection for anemia of chronic kidney disease. Drugs. 2004;64(5):499-509.
13. Sinha SD, Bandi VK, Bheemareddy BR, et al. Efficacy, tolerability, and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase III trial. BMC Nephrol. 2019;20(19):1-9.
14. Carrera F, Burnier M. Use of darbepoetin alfa in the treatment of anemia of chronic kidney disease: clinical and pharmacoeconomic considerations. NDT Plus. 2009;2(1):9-17.
15. Macdougall IC, Kai-Uwe E. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet. 2006;368:947-53. DOI:10.1016/S0140-6736(06)69120-4
16. Abracchio MP, Zanella A. Therapy perspectives. L’eritropoietina e la regolazione della massa eritroide. Adis a Wolter Kluwer business, 2006.
17. Locatelli F, Pozzoni P, Vecchio LD. Recombinant human epoetin beta in the treatment of renal anemia. Ther Clin Risk Manag. 2007;3(3):433-9.
18. Locatelli F, Covic A, Eckardt KU, et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2009;24(2):348-54. DOI:10.1093/ndt/gfn653
19. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial. Ann Intern Med. 1989;111(12):992-1000. DOI:10.7326/0003-4819-111-12-992
20. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 Suppl. 3):S11-145.
21. Locatelli F, Aljama P, Bárány P, et al.; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19 Suppl. 2:ii1-47. DOI:10.1093/ndt/gfh1032
22. Panichi V, Rosati A, Bigazzi R, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant. 2011;26(8):2641-8. DOI:10.1093/ndt/gfq802
23. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17(4):1181-91.
24. de Lurdes Agostinho Cabrita A, Pinho A, Malho A, et al. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. Int Urol Nephrol. 2011;43(3):835-40. DOI:10.1007/s11255-010-9805-9
25. Won HS, Kim HG, Yun YS, et al. IL-6 is an independent risk factor for resistance to erythropoiesis-stimulating agents in hemodialysis patients without iron deficiency. Hemodial Int. 2012;16(1):31-7. DOI:10.1111/j.1542-4758.2011.00635.x
26. Shankar A, Sun L, Klein BE, et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 2011;80(11):1231-8.
27. Stinghen AE, Bucharles S, Riella MC, Pecoits-Filho R. Immune mechanisms involved in cardiovascular complications of chronic kidney disease. Blood Purif. 2010;29(2):114-20. DOI:10.1159/000245636
28. Yilmaz MI, Solak Y, Covic A, et al. Renal anemia of inflammation: the name is self-explanatory. Blood Purif. 2011;32(3):220-5. DOI:10.1159/000328037
29. Bruggeman LA, Bark C, Kalayjian RC. HIV and the Kidney. Curr Infect Dis Rep. 2009;11:479-85.
30. Margolick JB, Jacobson LP, Schwartz GJ, et al. Factors affecting glomerular filtration rate, as measured by iohexol disappearance, in men with or at risk for HIV infection. PLoS One. 2014;9:e86311.
31. Ng DK, Jacobson LP, Brown TT, et al. HIV therapy, metabolic and cardiovascular health are associated with glomerular hyperfiltration among men with and without HIV infection. AIDS. 2014;28:377-86.
32. Lazarus Jeffrey V, Laut KG, Safreed-Harmon K, et al. Disparities in HIV clinic care across Europe: Findings from the EuroSIDA clinic survey. BMC Infect Dis. 2016;16:335. DOI:10.1186/s12879-016-1685-x
33. Mohan S, Herlitz LC, Tan J, et al. The changing pattern of glomerular disease in HIV and hepatitis C co-infected patients in the era of HAART. Clin Nephrol. 2013;79:285-91.
34. Markowitz GS, Nasr SH, Stokes MB, D’Agati VD. Treatment with IFN-alpha, -beta, or -gamma is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5:607-15.
35. Volberding PA, Levine AM, Dieterich D, et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004;38:1454-63.
36. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-23.
37. Kimel M, Leidy NK, Mannix S, Dixon J. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value in Health. 2008;11(1):57-75.
38. Henry DH, Beall GN, Benson CA, et al. Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy. Ann Intern Med. 1992;117(9):739-48. DOI:10.7326/0003-4819-117-9-739

В.В. Фомин* 

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*fomin_v_v_1@staff.sechenov.ru

________________________________________________

Victor V. Fomin*

Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*fomin_v_v_1@staff.sechenov.ru